Pharma Cash Keeps Flowing Into Ireland
MSD and Astellas have joined Lilly, Takeda and AstraZeneca in making major investments in Ireland this year.
You may also be interested in...
The Boston-based biotech is weighing up its options as the fall-out from its failed IPF candidate casts a shadow over Galecto’s future.
Getting on the best reimbursement pathway in the US will be vital for the UK company as it moves closer to approval and taking on the established players in the chronic obstructive pulmonary disease arena.
The French firm has followed up its recent acquisition of Swiss lung cancer specialist Vertical Bio by signing a pact with Vernalis.